Grimmel K, Richter E, Zilly W
Z Gastroenterol. 1979 Mar;17(3):154-61.
In 7 obese patients with an overweight of 53 +/- 19% of Broca we found a 2-fold enlarged apparent volume of distribution and a nearly 2-fold prolonged elimination halflife of hexobarbital; the hexobarbital plasma clearance however, which is nearly identical with the metabolizing capacity of the liver for hexobarbital, was not decreased. Phenobarbital induced the microsomal drugmetabolizing enzyme system in the fatty liver of genetically obese mice in the same way 2-3-fold as in the non-fatty liver of the lean littermates.
在7名超重53±19%(相对于布罗卡标准)的肥胖患者中,我们发现己巴比妥的表观分布容积增大了2倍,消除半衰期延长了近2倍;然而,与肝脏对己巴比妥的代谢能力几乎相同的己巴比妥血浆清除率并未降低。苯巴比妥诱导遗传性肥胖小鼠脂肪肝中微粒体药物代谢酶系统的方式,与诱导同窝瘦小鼠非脂肪肝中该系统的方式相同,增强了2至3倍。